Edition:
United Kingdom

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

163.87USD
12 Nov 2018
Change (% chg)

$-1.65 (-1.00%)
Prev Close
$165.52
Open
$165.90
Day's High
$165.99
Day's Low
$162.68
Volume
461,852
Avg. Vol
481,314
52-wk High
$197.00
52-wk Low
$142.83

Chart for

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.30
Market Cap(Mil.): $55,827.57
Shares Outstanding(Mil.): 337.29
Dividend: 0.72
Yield (%): 1.74

Financials

  AGN.N Industry Sector
P/E (TTM): -- 28.00 29.57
EPS (TTM): -0.58 -- --
ROI: -0.08 13.26 12.77
ROE: -0.30 15.04 14.47

Allergan says offers undervalue business units for sale, shares fall

Allergan Plc on Tuesday expressed disappointment in early offers from potential buyers for business units it has been trying to sell, and its shares fell more than 6 percent.

30 Oct 2018

Allergan says offers undervalue business units for sale, shares fall

Allergan Plc on Tuesday expressed disappointment in early offers from potential buyers for business units it has been trying to sell, and its shares fell more than 6 percent.

30 Oct 2018

UPDATE 3-Allergan says offers undervalue business units for sale, shares fall

Oct 30 Allergan Plc on Tuesday expressed disappointment in early offers from potential buyers for business units it has been trying to sell, and its shares fell more than 6 percent.

30 Oct 2018

Allergan CEO disappointed with early buyer interest in business units

Allergan Plc's Chief Executive Officer Brent Saunders said on Tuesday early buyer interest in its women's health and infectious diseases business units was below the price of what he believes the businesses are valued.

30 Oct 2018

Allergan CEO disappointed with early buyer interest in business units

Allergan Plc's Chief Executive Officer Brent Saunders said on Tuesday early buyer interest in its women's health and infectious diseases business units was below the price of what he believes the businesses are valued.

30 Oct 2018

Allergan CEO disappointed with early buyer interest in business units

Oct 30 Allergan Plc's Chief Executive Officer Brent Saunders said on Tuesday early buyer interest in its women's health and infectious diseases business units was below the price of what he believes the businesses are valued.

30 Oct 2018

Botox-maker Allergan's revenue drops 3 pct

Oct 30 Allergan Plc reported a 3 percent drop in quarterly revenue on Tuesday, as its faces increasing competition for its Alzheimer's treatment Namenda and other branded drugs.

30 Oct 2018

Drugmakers tout new medicines as eye disease battle intensifies

ZURICH Switzerland's Roche and Novartis and other drugmakers are touting new treatments for a blindness-causing disease that hits millions of older people, as patent expiries are set to open up one of medicine's most lucrative markets.

29 Oct 2018

Drugmakers tout new medicines as eye disease battle intensifies

ZURICH Switzerland's Roche and Novartis and other drugmakers are touting new treatments for a blindness-causing disease that hits millions of older people, as patent expiries are set to open up one of medicine's most lucrative markets.

29 Oct 2018

UPDATE 2-Drugmakers tout new medicines as eye disease battle intensifies

* Along with new drugs, generic copies also in the works (Adds details on U.S. market)

29 Oct 2018

Earnings vs. Estimates